BioVentureHub’s Post

I vividly remember February 15, 2018, when Roche closed a Series C round, acquiring Flatiron Health for $1.9 billion and integrating it as a subsidiary while allowing it to operate as a separate legal entity. Two years prior, Roche had completed the acquisition of a 62.8% stake in Foundation Medicine Inc. -Cohomprensive Genomic Profile Test (Next Gen. Seq.) - , a company based in Cambridge, Massachusetts, near Boston. These acquisitions represented different business models compared to Roche’s traditional value chain. As part of my executive MBA at POLIMI Graduate School of Management, we decided to develop a #projectwork on "revising the business model to create an end-to-end integration of clinical and #genomic data from #NGS ( Next Generation Sequencing) tests #EHRs and #RWD. We highlighted the challenges and proposed solutions to manage different asset and Innovative solutions as traditional DrugMaker Company. Today, thanks to #syntheticdata, everything is much simpler and probably Flatiron need to evaluate scaling and internationalization approaches. Reading the recent news about Roche’s desire to review its agreements with Flatiron, I feel nostalgic and hopeful that companies like Flatiron or Syapse, also in Roche’s current investment portfolio, can find integration solutions through a redesigned Go-to-Patient and Go-to-Market model. This would enhance the future portfolio and pipeline value. Thanks again to Prof. Emanuele Lettieri and Prof. Federico Frattini, who contributed to that work, which remains valuable today for the principles of revising #businessmodels in drug innovation and #InnovativeHealthSolutions support of the portfolio strategy. Special thanks to my EMBA mates that contributed to reading, inspiring, driving, writing, having fun, think, smiling, leading, ..... Stefano Allevi | Andrea Carrettoni | Davide Mazzali - EMBA | Alessandro Braga | Marco Berci | Pietro Ponti | Alessandro Sapio | Matteo Vecchio | A huge thank you goes to the #leaders and #enablers of that time - Patrizia Olivari | Adriana Dantas | Pedro Goncalves | Alessandra Bianchi | Diego Vailati Venturi | Maurizio de Cicco - who, as visionary leaders, saw the future and the tangible impact on patients lives, allowing me to work on this model.

Congratulations to ECRIN (European Clinical Research Infrastructure Network) and GreCRIN _ECRIN and to all the speakers! CoLAB TRIALS was fortunate to participate in the International Clinical Trials Day (ICTD) 2024. This year it was focused on Data Centric Clinical Research, setting the stage to discuss the impacts, benefits and challenges of the use of data and technology, the integration of the new technical assets and novel approaches, eHealth, data science, GDPR, and collaboration between parties taking into account the multi-stakeholder perspectives from industry, authorities, patients and society. #ClinicalTrials #Innovation #DigitalHealth #ClinicalResearch

💡 My Top 3 takeaways from attending #BioEurope Spring this year: 🤝 Last month, I had the chance to attend BioEurope Spring 2024 in Barcelona as a representative of the STADA Group! It was an enriching experience that provided invaluable networking opportunities, was filled with insightful discussions, and gave a glimpse into the future of healthcare. 1. Change is the only CONSTANT: Over the past year, the landscape of the biotech and pharma industries has undergone significant transformations. The S&P Biotech Index has achieved unprecedented growth, surging by +45% within the past year. Acquisitions of R&D-stage biotechnology firms soared to record levels, totalling 48 transactions and an expenditure of $78 billion in 2023. Concurrently, the tally of FDA approvals for novel therapeutics reached 64 during the same period. Witnessing these shifts firsthand at BioEurope reaffirmed the importance of staying ahead of the curve and embracing change as an opportunity for growth. 🚀 2. Emerging Trends: One of the most exciting aspects of attending BioEurope was gaining insights into the growing trends shaping the future of healthcare. From precision medicine to the increasing emphasis on sustainability in drug development, it's inspiring to see the industry's commitment to innovation and patient-centric approaches. The formulation of strategy necessitates an ongoing evolution, predicated not solely on perceived requirements but also on market demands. Moreover, the landscape of therapeutic areas is undergoing discernible shifts. Many pharmaceutical enterprises, having primarily pivoted towards Oncology over the last decade, are now reorienting their focus towards Central Nervous System (CNS) disorders, evincing substantial activity in Neurodegenerative diseases and Neuropsychiatry. 💉 3. AI in Healthcare: Artificial Intelligence continues to profoundly reshape the healthcare landscape, emerging as a central topic of discourse at the event. From advancing drug discovery and development to refining personalised treatment strategies, AI continues to gain importance. It is imperative to recognize AI not as a mere buzzword, but as a tool for optimising data analysis strategies. The future of drug development is poised to be AI-driven, albeit without disregarding traditional approaches entirely. Biomarkers will assume a pivotal role in the forthcoming years, ensuring precise therapeutic targeting and efficacy. Hence, harnessing cutting-edge technologies is paramount to augmenting patient outcomes and streamlining efficiencies across the value chain. 🧠 Engaging with industry leaders, innovators, and experts deepened my understanding of the challenges and opportunities facing our sector, empowering me to drive meaningful change. Looking forward to leveraging these learnings to shape our strategies and initiatives for a brighter, more innovative future in healthcare! 🌟 #healthcare #biotech #pharma #AI #conference #drivingchange

A Rare Opportunity to Make a Real Difference at Chiesi's Pharma Day! I had a fantastic time attending Chiesi's Pharma Day today and wanted to express my sincere gratitude to MassBio and the entire Chiesi USA, Inc. team for hosting such an informative and engaging event. 🔶 Especially for #Regulatory professionals like me, understanding rare diseases is crucial!! 🔶 This knowledge is crucial for promoting breakthrough designation and helping patients with rare diseases: ◽ Fast-Track Development: Regulatory expertise helps navigate the pathway for Breakthrough Designation. This designation streamlines the approval process for drugs targeting serious or life-threatening conditions with promising potential. ◽ Tailored Endpoints: Rare diseases often lack established treatment benchmarks. Regulatory knowledge empowers professionals to propose alternative endpoints (like biomarkers) for trials, which can expedite approval. ◽ Addressing Unmet Needs: Regulators familiar with rare diseases understand the urgency for new treatments. This knowledge facilitates focused discussions and efficient data collection to secure faster approval. For those who couldn't make it, Chiesi's Pharma Day provided a unique opportunity to gain valuable insights into their R&D strategy, target therapeutic areas within rare diseases (including hematology, immunology, and ophthalmology!), and partnering capabilities. The fireside chat with Luke Gruenert Fernando Tricta about Chiesi's Strategic Innovation Unit was particularly insightful, and the panel discussion with Ester Caffarel-Salvador, PhD Giacomo Chiesi Alberto Parisi Helen Phillips Stuart Siedman on the exciting opportunities and challenges in rare diseases sparked some great conversations. It was inspiring to connect with so many passionate leaders and innovators who are all dedicated to accelerating advancements in rare diseases. A huge thank you to MassBio for facilitating these unparalleled connections at Chiesi Pharma Days! #PharmaDay #Chiesi #RareDiseases #MassBio #Science #Innovation #Regulatory

Belgium’s leading contribution to life science innovation and growth in Europe: The local biotech industry keeps leaping forward, showcasing a great display of innovation and growth that positions the country as an influential powerhouse in the European biotech landscape (see press, e.g., https://lnkd.in/dgECRDgJ). With a deep-rooted life science legacy, the country is witnessing a surge driven by multiple successes of local biotech firms. But what are the ingredients for this success story? > Local Sector Champions: Companies such as Galapagos are leading the charge with new drug candidates that could potentially revolutionize treatments for inflammatory diseases. Argenx following suit, specializing in antibody-based therapies that are pioneering immunological research. And well-established UCB completing the examples trinity with its neurological and immunology products that are setting new benchmarks in healthcare > Academic Excellence: Institutions like KU Leuven and Ghent University (through VIB) are not just academic halls but innovation incubators. Their vigorous research programs are spawning spin-offs that champion novel biotech solutions, translating meticulous research into therapies and products that address real-world health challenges > Startup Incubation: Innovative endeavors are not limited to industry giants. Startups like Hyloris are reimagining existing pharmaceuticals to improve patient outcomes, while Aphea.Bio is breaking new ground in the agriculture sector by harnessing microbial technology to enhance crop resilience and productivity > Investment Support: While funding remains as one of the key challenges in the sector, especially smaller companies have local public funding support programs at their reach through cluster initiatives. These investments are critical, enabling companies to attract additional private funding and to pursue growth investments (e.g. R&D) All these factors contribute to the success of Belgian life science firms and the country's global recognition across various medical fields in pharma, diagnostics, medical devices and e-health (e.g. in oncology, immuno-therapy, neurology, women's health) as a source of medical innovation with the potential to benefit patients worldwide. Roland Berger Belgium happily supports local and international Health players navigate their most critical challenges. Please feel free to contact our local and international experts: Grégoire Tondreau Astrid Böhlke Jelle Heyvaert Michael Baur #rolandberger #rbhealthbelgium #pharmaceuticals #lifescience #medtech #innovation

The World Orphan Drug Congress USA unfolds today at the Boston Convention and Exhibition. With over 2,400 participants coming together, the main theme of "Breaking down silos and fostering collaboration to help rare disease patients" sets the stage for impactful discussions. The conference will talk about various interesting topics including advanced therapies in commercialization and clinical development, as well as diagnosis and discovery with the use of #AI and machine learning. Among the key highlights are: 🌟 Patient Data: With the significance of real-world data (RWD/RWE) in rare disease management. 🌟 Rare Oncology: Precision diagnosis is revolutionizing the rare cancer landscape, emphasizing the necessity for collaboration among stakeholders.  🌟 Commercial Strategies: Exploring effective commercial approaches for orphan products is imperative.  🌟 Rare Disease Advocacy: Advocacy efforts, centered around patients, are paramount. Understanding the challenges faced by rare disease patients and organizations is key.  🌟Digital Health & Artificial Intelligence: Approaches in AI and digital health span the full development life cycle of drug development and commercialization. The #WODC24 brings together leading pharmaceutical and biotech companies, government and regulatory authorities, patient advocacy groups, payers, investors, and solution providers. The conference is a place to meet and brainstorm ways to advance orphan drug development and improve access to life-saving therapies. WODC aligns with Clinakos Inc. dedication to advancing rare disease research and improving patient outcomes. Our focus on #PatientData and Medically Smart AI drives our mission. #pharmaceuticals #pharmaceutical

I am thrilled to share that I have accepted an invitation to speak on behalf of TauC3 Biologics at the prestigious 24th annual Bio€quity Europe Conference, taking place from May 12-14, 2024, in the beautiful city of San Sebastián, Spain. Bio€quity serves as a platform for industry leaders, investors, and innovators to come together, exchange ideas, and drive collaboration. I am honored to have the opportunity to discuss TauC3 Biologics’ pioneering precision immunotherapeutic strategy and development candidate. TBL-100 is an  extremely potent humanized antibody in preclinical development for the treatment and diagnosis of tau-related frontotemporal dementia (FTD-tau) and progressive supranuclear palsy (PSP). Both are devastating and fatal neurodegenerative diseases whose symptoms may include memory loss, behavioral changes, difficulties with movement and problems with language. Headquartered at the Stevenage Bioscience Catalyst, TauC3 Biologics is bringing together world-class expertise and drug development talent to turn its vision into a reality and is poised for efficient preclinical development and subsequent early clinical development of TBL-100, with the aim of rapidly demonstrating safety and proof of concept.  The company is seeking investors and partners to accelerate development and commercialization. I look forward to engaging with investors and other stakeholders interested in learning more about TauC3 Biologics’ therapeutic and diagnostic pipeline and helping us deliver for patients currently lacking effective treatments.   #Bio€quity #TauC3Biologics#StevenageBioscience  

🆕 During the month of May, at the #BioRegionCatalonia, outstanding presentations, #investment, #business partnerships and other notable news from the ecosystem have occurred. Let’s review them 👇 🔺 #Biocat presented the new Catalan Health System innovation Access Program (#PASS), a project that will help streamline access to the Catalan Healthcare System for #innovation by identifying, prioritizing and guiding it. 🔺 The investment fund XY Booster Group has chosen #Catalonia for its new innovation hub. Plus, Novartis has inaugurated new offices in #Barcelona, and ESTEVE will expand its factory in Celrà (Girona). 🔺 Loop Diagnostics, a company from the #dHEALTHBcn program, has been granted UKCA marking as an in vitro diagnostic tool for its SeptiLoop device, making it eligible for clinical use in the UK. 🔺 Ysios Capital took part in a €46 million round in NEMO Therapeutics LLC, a company developing antibodies to fight viral diseases. COLUMBUS VENTURE PARTNERS,S.G.E.I.C., S.A.U. closed its 4th fund with €150 million. 🔺 ABLE Human Motion closed an operation for 💰 €875,000, while other startups have also secured #funding. 🔺 GigaGen Inc, a subsidiary of Grifols, kicked off a clinical trial on its first oncology drug to treat metastatic or locally advanced solid tumours. 🔺 OneChain Immunotherapeutics, a #biotech developing CAR-T cell therapies for oncology diseases, began its first clinical trial on OC-1. Read all the news at the wrap up of May: 🗞 https://lnkd.in/d_KjuQ9s

➡️➡️ Interested in #socialmedia in the #oncology space? Check out our #ESMO24 report! http://dlvr.it/TG48BL 📥 . 🚀 Our team monitored and analyzed ESMO-related posts on X (previously #Twitter) before, during, and after the event, and here are some key takeaways: 🔍 Key hashtags: Online conversations spotlighted #LCSM, #BCSM, #breastcancer, and #prostatecancer, with notable attention on education-related hashtags. Top Discussion Themes: #Efficacy dominated discussions at 21% 📊, followed by #Data and #clinicaltrials/#studies, both at ~16% 🔬. Leading Voices: #Physicians dominated the conversation at 87% 🎤, followed by #researchers at 7% 🔬. Audience Sentiment: Overwhelmingly positive! 😄 Two-thirds of posts celebrated research breakthroughs & networking opportunities. Text Analytics: #ESMO2024 heavily focused on #lungcancer and #breastcancer, with much discussion around #chemotherapy and #immunotherapy (#pembrolizumab!). 👉 Interested in #socialmedia coverage during conferences? We cover multiple #therapyareas and events! Send us a message at [email protected]! Abbott AbbVie Accord Healthcare Amgen Astellas Pharma AstraZeneca Bayer BeiGene Bicycle Therapeutics BioNTech SE Boehringer Ingelheim Bristol Myers Squibb Caris Life Sciences Daiichi Sankyo Europe GmbH Dr. Reddy's Laboratories Eisai US Eisai EMEA Eli Lilly and Company Exelixis Gilead Sciences GSK Ipsen Jazz Pharmaceuticals Johnson & Johnson Massive Bio MENARINI Group Merck Group EMD Serono, Inc. Moderna MSD Novartis Novocure Owkin PathAI Pfizer Regeneron Roche Sanofi Servier Pharmaceuticals Takeda Oncology #HealthcareConsulting #ESMO2024 #SocialListening #DigitalHealth #MedicalEducation #LucidQuest #CompetitiveMarketing